media – Page 21 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The nine-valent HPV vaccine for men is now available

After the four-valent HPV (human papillomavirus) vaccine was opened to men, on April 14, Merck China announced that Gardasil® 9 [nine-valent human papillomavirus vaccine (brewer’s yeast)] (hereinafter referred to as “nine-valent HPV vaccine”) has been approved for marketing by the National Medical Products Administration for multiple new indications and is suitable for males aged 16 to 26. This means that China has ushered in the first nine-valent HPV vaccine that can be used for male vaccination. Gardasil® 9 has become the first and currently the only approved nine-valent HPV vaccine in China that can be used for males and females of appropriate age, marking that China has officially entered a new stage of “joint prevention of HPV-related cancers and diseases for both men and women”. Although men do not develop cervical cancer, they are the main carriers of HPV virus. Globally, the male genital HPV infection rate is higher than ...
- Source: drugdu
- 192
- April 16, 2025
【EXPERT Q&A】What are the procedures and qualifications required for the export of domestic drugs to East Africa?

Drugdu.com expert’s response: Export Process and Qualification Requirements for Chinese Pharmaceutical Products to East Africa (2025 Update) Based on the latest East African Community (EAC) pharmaceutical regulations and China’s White Paper on Medical Exports to Africa: I. Pre-Qualification Preparation (3–6 Months) Production Compliance: 2025 China GMP Certification: Mandatory adoption of quantum-encrypted traceability modules for data integrity. Submit 36-month stability test reports under tropical conditions (40°C/75% humidity). WHO Prequalification (PQ): Required for antimalarial/HIV drugs in EAC public tenders. Review周期缩短至4.2 months (30% faster than 2020). Export Documentation Free Sale Certificate (FSC): Issued by provincial authorities, apostilled, and blockchain-verified (recognized by Kenya Revenue Authority). Religious Compliance: Halal certification (EAC Islamic Affairs Council) for animal-derived ingredients; separate approval for alcohol-based formulations. II. EAC Regional Market Access Centralized EAC Review (Core Step) MRH-01 Dossier Submission: Include multi-country clinical trial data (minimum 2 EAC nations, e.g., Rwanda’s Kigali University Hospital). Localized bilingual packaging (English/Swahili + Braille). Fast-Track Eligibility: 50% faster review for drugs in the China-Africa Public ...
- Source: drugdu
- 140
- April 16, 2025
2025 Wuzhen Health Conference | Tasly Achieves Multiple Awards, Driving a New Future of Medicine and Health with Innovation

From April 8th to 12th, 2025, Wuzhen, a water town in Jiangnan, welcomed the annual grand event in the field of medicine and health – Wuzhen Health Conference. This industry grand event, which gathers industry elites, experts, scholars, and well-known enterprises, is an important platform for gaining insights into industry trends and exchanging innovative ideas. Tianshili Pharmaceutical Group (hereinafter referred to as “Tianshili”) won multiple awards at the conference with innovative achievements in brand strategy, product positioning, market channels, and other aspects, becoming the focus of the audience. Brand Strategy Innovation: Shaping the Influence of Innovative Traditional Chinese Medicine Drugs In terms of brand strategy, Tasly always regards innovation as the core driving force and is committed to building a Chinese medicine brand with international influence. Winning the title of “VIP Strategic Cooperation Enterprise” at the 2025 Wuzhen Health Conference is a high recognition of its brand strength and ...
- Source: drugdu
- 113
- April 15, 2025
Boya Biotechnology plans to list and transfer 80% equity of its subsidiary; Two drugs from Hengrui Pharmaceutical have been approved for clinical trials | Medical Early Reference

NO.1 Boya Biotechnology plans to publicly list and transfer 80% equity of its subsidiary On April 13th, Boya Biotechnology announced its intention to transfer 80% equity of Jiangxi Boya Xinhe Pharmaceutical Co., Ltd. (referred to as “Boya Xinhe”) through listing on the Shanghai United Property Rights Exchange, with an initial listing amount of approximately 213 million yuan. Boya Xinhe was established in 2014, and its main business is the R&D, production and sales of anti infection, diabetes, cardio cerebrovascular drugs. After the equity transfer, the company holds 10.6869% of the equity of Boya Xinhe, and its wholly-owned subsidiary Jiangxi Boya Pharmaceutical Investment Co., Ltd. holds 9.3131% of the equity of Boya Xinhe. Boya Xi nhe will no longer be included in the company’s consolidated statements. Comment: From January to December 2024, Boya Xinhe’s operating revenue was 10.1729 million yuan, total profit was -34.6187 million yuan, and net profit was ...
- Source: drugdu
- 77
- April 15, 2025
API China

Organiser: Reed Sinopharm Exhibitions Time: May 21–23, 2025 Address: No. 380, Yuejiang Middle Road, Haizhu District, Guangzhou City Exhibition hall: Canton Fair Complex – Pazhou Hall, Guangzhou Product range: Pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical excipients, natural extracts, chemical reagents, intermediates, fine chemical raw materials, traditional Chinese medicine raw materials, food raw materials and additives, veterinary drug raw materials, feed raw materials and additives, health product raw materials and additives, biotechnology, pharmaceutical R&D services, contract custom manufacturing services, registration and pharmaceutical affairs services, training services About API China： China International Pharmaceutical Active Pharmaceutical Ingredients Exhibition (API China), as the longest-standing exhibition in China’s pharmaceutical sector, was inaugurated in 1968. The exhibits not only cover over 50,000 types of APIs across 24 major categories but also encompass all excipients, functional ingredients, internal and external packaging materials, as well as production and testing equipment required for the manufacturing of pharmaceuticals and health supplements.
- Source: drugdu
- 111
- April 15, 2025
Obtained drug clinical trial approval notice

Hengrui Medicine announced on the evening of April 13 that the company received the “Notice of Approval for Clinical Trial of Drugs” issued by the National Medical Products Administration for HRS-9190 for injection, and will conduct clinical trials in the near future. HRS-9190 for injection is a Class 1 new drug for intraoperative medication, used for tracheal intubation during the induction period of general anesthesia and maintaining skeletal muscle relaxation during surgery. The company announced on the same day that its subsidiaries Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia Biotechnology Co., Ltd. received the “Notice of Approval for Clinical Trial of Drugs” issued by the National Medical Products Administration for SHR-3792 injection, and will conduct clinical trials in the near future. SHR-3792 injection is an innovative anti-tumor drug candidate independently developed by the company, which has shown good anti-tumor activity in preclinical animal models. Upon inquiry, no similar drugs ...
- Source: drugdu
- 96
- April 15, 2025
Merck’s nine-valent HPV vaccine approved for marketing in China for male indications

On April 14, MerckAnnounced that Gardasil® 9 [9-valent human papillomavirus vaccine (crysogenyces cerevisiae)] (hereinafter referred to as “9-valent HPV vaccine”) has been approved for marketing by the National Medical Products Administration for multiple new indications, and is suitable for males aged 16 to 26. This approval makes Gardasil® 9 the first and currently the only 9-valent HPV vaccine approved in China for males and females of appropriate age. https://finance.eastmoney.com/a/202504143375989893.html
- Source: drugdu
- 103
- April 15, 2025
Servier’s “Oncology Business”

Recently, Servier spent $780 million to acquire BDTX-4933, a small molecule drug in Phase 1 clinical trials targeting RAS mutations and RAF changes in solid tumors, from Black Diamond Therapeutics. Today, Servier’s competitive position is threatened by challenges in the chronic disease drug market, and it is actively looking for a new way forward, with the latest goal of entering the field of oncology. In recent years, Servier has continuously strengthened its oncology pipeline through acquisitions and introductions, and has become a “dark horse” in the field of oncology treatment that cannot be underestimated. IDH inhibitor frontrunner Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the tricarboxylic acid cycle. There are three isoenzymes of IDHs, namely IDH1, IDH2 and IDH3. The functional loss caused by mutations in IDH1 and IDH2 will directly affect the product composition – α-ketoglutarate is converted into the carcinogenic metabolite 2-hydroxyglutarate, promoting the occurrence of ...
- Source: drugdu
- 79
- April 15, 2025
The world’s first new FcRn antagonist formulation is approved for marketing in the United States

Recently, Zai Lab’s partner argenx announced that the U.S. FDA (U.S. Food and Drug Administration) has officially approved the marketing of Efgartigimod prefilled subcutaneous injection formulation for the treatment of adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are positive for acetylcholine receptor (AChR) antibodies. Efgartigimod is the world’s first approved FcRn antagonist. Previously, its intravenous formulation (IV) and subcutaneous formulation (SC) have been approved for marketing by the FDA (U.S. Food and Drug Administration). The approval of the prefilled subcutaneous injection formulation further enriches the product form of Efgartigimod and improves the convenience of patients’ medication. This not only consolidates Argenx’s leading position in the field of FcRn antagonists, but also brings new market opportunities to Zai Lab. As Agamod continues to expand in the global market, Zai Lab is expected to share its growth dividend in the field of rare diseases through ...
- Source: drugdu
- 81
- April 15, 2025
Midea Group established the Medical Division and released Midea Medical’s annual new products

On April 8, the 91st China International Medical Equipment Fair (CMEF) opened. During the exhibition, Midea Medical held the “AI All-dimensional Intelligent Transformation 2025 Midea Medical Annual New Product Release and China Backbone Guardian Plan Launch Meeting” and officially announced the establishment of Midea Medical Division. As one of the six major business sectors of Midea Group, Midea Medical is a major breakthrough in Midea Group’s diversified development strategy. Midea Medical has the accumulation of Wandong Medical in medical diagnostic equipment and intelligent imaging solutions, Kuka Medical’s cutting-edge technology in the field of surgical robots and rehabilitation robots, Midea Biomedical’s professional advantages in medical cold chain refrigeration, Swisslog Medical’s mature solutions in hospital logistics and pharmacy automation, and Midea Building Technology’s strength in the construction and operation of smart hospitals. The synergy of these advantageous resources will further enhance Midea Medical’s industrial competitiveness. Midea Medical will also rely on Midea ...
- Source: drugdu
- 136
- April 14, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.